Relmada Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BST:4E2 Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
11 Sep 24	Buy€135,958	Maged Shenouda	Individual	53,432	€2.68
11 Sep 24	Buy€358,843	Sergio Traversa	Individual	140,000	€2.72
09 Sep 24	Buy€58,644	Paul Kelly	Individual	25,000	€2.35
09 Sep 24	Buy€30,142	Charles Casamento	Individual	13,000	€2.32
31 Jan 24	Buy€139,103	Charles Ence	Individual	38,970	€3.74
31 Jan 24	Buy€115,873	Maged Shenouda	Individual	32,675	€3.75
31 Jan 24	Buy€356,456	Sergio Traversa	Individual	100,000	€3.68

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 4E2?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	2,633,675	8.73%
Institutions	12,482,365	41.4%
General Public	15,058,162	49.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 43.71% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
6.3%	Kevin Kotler	1,899,930	€693.7k	0%	no data
4.32%	Franklin Resources, Inc.	1,302,151	€475.4k	28.6%	no data
4.16%	The Vanguard Group, Inc.	1,256,705	€458.8k	0%	no data
3.93%	Acadian Asset Management LLC	1,186,452	€433.2k	-0.58%	no data
3.32%	Parsons Capital Management, Inc.	1,002,695	€366.1k	2.74%	0.02%
2.43%	Palo Alto Investors LP	732,400	€267.4k	0%	0.04%
2.24%	Deep Track Capital, LP	674,833	€246.4k	-45.4%	0.01%
1.88%	BlackRock, Inc.	567,880	€207.3k	-0.95%	no data
1.86%	Millennium Management LLC	561,826	€205.1k	773%	no data
1.62%	Vestal Point Capital, LP	490,000	€178.9k	-59.2%	0.01%
1.59%	Opaleye Management Inc.	480,000	€175.2k	-20%	0.03%
1.27%	Sergio Traversa	384,024	€140.2k	57.4%	no data
1.04%	JPMorgan Chase & Co, Brokerage and Securities Investments	315,059	€115.0k	-10.7%	no data
1.01%	Geode Capital Management, LLC	304,502	€111.2k	16.9%	no data
0.8%	Two Sigma Advisers, LP	242,500	€88.5k	-17.1%	no data
0.75%	Deutsche Asset & Wealth Management	224,846	€82.1k	0%	no data
0.7%	Paul Kelly	212,295	€77.5k	13.4%	no data
0.68%	Bank of America Corporation, Asset Management Arm	206,658	€75.5k	-0.03%	no data
0.63%	Two Sigma Investments, LP	191,315	€69.8k	-5.88%	no data
0.6%	Bridgeway Capital Management, LLC	181,077	€66.1k	0%	no data
0.58%	Shay Capital LLC	175,547	€64.1k	0%	0.02%
0.55%	RBF Capital LLC	165,474	€60.4k	0%	no data
0.52%	Jacobs Levy Equity Management Inc	157,672	€57.6k	99.9%	no data
0.48%	Barclays PLC Private Banking & Investment Banking Investment	145,999	€53.3k	0%	no data
0.42%	UBS Asset Management AG	126,385	€46.1k	-1.88%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/24 00:55
End of Day Share Price	2024/12/05 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Relmada Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Robert LeBoyer	Aegis Capital Corporation
Maxim Jacobs	Edison Investment Research
Yatin Suneja	Guggenheim Securities, LLC